Previous close | 3.0600 |
Open | N/A |
Bid | 1.7500 |
Ask | 5.0000 |
Strike | 7.50 |
Expiry date | 2024-06-21 |
Day's range | 3.0600 - 3.0600 |
Contract range | N/A |
Volume | |
Open interest | 2 |
BOSTON, May 30, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“the Company” or “Inozyme”), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, today announced Doug Treco, Ph.D., CEO and Chairman of Inozyme, will present at the Jefferies Global Healthcare Conference on Thursday, June 6, 2024 from 12:30-12:55 pm ET. A live webcast of the presentation can be accessed from the
BOSTON, May 23, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“the Company” or “Inozyme”), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, today announced that the Company will present recently announced topline data from the Company’s ongoing Phase 1/2 clinical trials of INZ-701 in adults with ENPP1 Deficiency and ABCC6 Deficiency (manifesting as pseudoxanthoma elastic
BOSTON, May 08, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“the Company” or “Inozyme”), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, today announced Doug Treco, Ph.D., CEO and Chairman of Inozyme, will participate in a fireside chat at the Bank of America Securities 2024 Health Care Conference on Wednesday, May 15, 2024 from 6:40-7:10pm ET / 3:40-4:10pm PT. A live